Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
General19 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
General19 hours agoWhy the nation needs the Nationals to ditch Net Zero
-
General19 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News23 hours agoBrisbane rising on global rankings, but still behind southern capitals